Acuvi (ACUVI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Apr, 2026Executive summary
Focused on high-precision motion solutions for sectors including space, defense, healthcare, and semiconductors, with three business units: TPA Motion, PiezoMotor, and Sensapex.
Revenue for Q1 2026 was SEK 51.2 million, nearly unchanged year-over-year, reflecting a stable business base.
EBITDA dropped to SEK 3.3 million (6% margin) from SEK 10.4 million (20% margin) year-over-year, mainly due to higher costs.
Strategic focus is shifting toward profitability, stronger cash flow, and a clearer commercial structure, including a transition from distributor-led to direct sales.
Emphasis on building long-term partnerships and customer stickiness.
Financial highlights
Q1 net sales were SEK 51.2 million, flat year-over-year, with stable order intake.
Gross profit was SEK 26.7 million (52% margin), down from SEK 30.6 million (60% margin) year-over-year.
Operating loss of -SEK 7.6 million, impacted by accelerated depreciation of certain intangible assets.
Free cash flow improved to SEK 9.5 million from SEK 3.2 million, driven by positive working capital changes.
Earnings per share were -0.08 SEK, compared to 0.12 SEK in Q1 2025.
Outlook and guidance
Targets (not formal guidance) call for 10%-15% top-line growth, with higher targets in some areas.
EBITDA target for 2026 is set at SEK 37–50 million.
High internal targets for growth across regions and business units, with a focus on profitable expansion and higher-margin proprietary products.
APAC region expected to grow 50%-100% by year-end if current trends continue.
Management expects continued positive trends in PiezoMotor and strong customer interest in semiconductor and space industries.
Latest events from Acuvi
- Net sales up 16%–18%, Q4 up 25%; adjusted EBITDA positive, 2026 targets focus on growth.ACUVI
Q4 202526 Feb 2026 - Q3 2025 revenue up 32% year-over-year, with robust OEM/Industrial growth and margin gains.ACUVI
Q3 202526 Feb 2026 - Direct sales focus and cash flow positivity set the stage for ambitious growth targets.ACUVI
Business Update20 Nov 2025 - Q2 revenue and margins rose, driven by record orders and strategic direct sales expansion.ACUVI
Q2 202521 Aug 2025 - Stable Q3 margins, strong cash flow, and IFRS transition support positive 2024 outlook.ACUVI
Q3 202413 Jun 2025 - Sales declined but margins improved; new partnerships and capital support future growth.ACUVI
Q2 202413 Jun 2025 - Stark Q1-tillväxt och ökad direktförsäljning väntas driva fortsatt expansion.ACUVI
Q1 20256 Jun 2025 - Margins improved and 2025 EBITDA is set for strong growth on robust US demand.ACUVI
Q4 20245 Jun 2025